Firmagon - (80 mg/vial and 120 mg/vial; Powder, Subcutaneous)

Generic Name	Degarelix	Innovator	Ferring
Dosage	80 mg/vial and 120 mg/vial; Powder, Subcutaneous	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
********* ****	*** \ *********	*** **, ****	*** ** ** / ******* ** **	****	****** **** ********
***** ******	** \ **	*** **, ****	*******	****	*** ****** *** ****
******* ******	** \ **	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events